Description

Simple

Information currently not available.

Clinical

Information currently not available.

Overview

AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

Pharmacology

Indication

For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.

Pharmacodynamic

Oral administration of AC3056 results in dose-dependent antioxidant activity and was well tolerated. In 2002, positive results were reported from a phase I trial. In the double-blind, placebo-controlled, crossover trial, 14 healthy subjects received an oral formulation of AC3056 in a dose-escalating... Read more

Mechanism of action

Information currently not available.

Absorption

Absorbed following oral administration.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type

Contraindications

Information currently not available.

Food Interactions

Information currently not available.